<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910219-0040</DOCNO><DOCID>910219-0040.</DOCID><HL>   Technology Brief -- Amgen Inc.:   EC Regulatory Body Grants   Approval to Drug Neupogen</HL><DATE>02/19/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   AMGN EUROP</CO><IN>DRUG MANUFACTURERS (DRG)</IN><LP>   Amgen Inc. said it received approval for its geneticallyengineered drug, Neupogen, from a regulatory body of theEuropean Community called the Committee for ProprietaryMedicinal Products.   The approval isn't binding on the community's 12 members,who must individually authorize sale of the drug in theirrespective countries. Amgen said the CPMP approval is similarto a positive recommendation by an advisory committee of theU.S. Food and Drug Administration.</LP><TEXT>   Neupogen is Amgen's brand name for granulocyte colonystimulating factor, or G-CSF, a molecule that stimulates thegrowth of white blood cells. The CPMP approval is for use ofNeupogen in cancer patients to mitigate a side effect ofchemotherapy.   Amgen said it hopes that many, if not most, of theEuropean community members will approve the sale of Neupogenwithin six months. In December, an FDA advisory committeerecommended that the agency approve the drug for U.S.commercial sale. Amgen, which is based in Thousand Oaks,Calif., said it expects FDA approval before the end of nextmonth.</TEXT></DOC>